We identified a specific type of T cell called TH40 that loses regulation and becomes expanded in several affected subjects. Elevated numbers of TH40 cells have consistently been shown to lead to and sustain the auto-inflammation found in virtually all autoimmune disorders.
A Safer Way to Treat Inflammation
The antibodies used in current treatments notoriously cross-react with unintended targets and their huge molecules that must clear renal systems. However, due to the size of monoclonal antibodies, the treatment itself can become immunogenic, i.e., the monoclonal antibody causes an immune attack on itself.
Op-T has found a treatment that does not use monoclonal antibodies. We have developed small peptides that modulate but do not eliminate inflammatory cells. This approach constitutes a new way to target a highly inflammatory pathway without adverse effects.
Op-T’s proprietary new therapeutic has been proven in various pre-clinical tests in animals to restore T cell levels to their normal range and reduce the complications from inflammation. With regulation of this sub-set of T-Cells we have in cases been able to reverse diabetes in some early-stage mouse models of T1D while in other models the drug has proven therapeutic in controlling glucose, reducing insulin requirements, and reducing complications in Diabetes Mellitus in companion dogs.
In human clinical trials we have completed a Phase 1a study and are currently on track to complete a Phase 1b clinical trial by the end of 2023. In the Phase 1a and thus far in the Phase 1b study the therapeutic has proven safe for use at varied dosage levels.